ReviewHematology. American Society of Hematology. Education Program2025
Update in the diagnosis of complement-mediated thrombotic microangiopathy/atypical hemolytic uremic syndrome.
Review in Hematology. American Society of Hematology. Education Program, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neutrophil Extracellular Traps Aggravate Injury in Complement-Mediated Thrombotic Microangiopathy.Journal of the American Society of Nephrology : JASN · 2026Article
- Thrombotic Microangiopathy And Hypertensive Emergency After Cocaine Use: A Case Report.Journal of Brown hospital medicine · 2026Article
- Case Report: Complement-mediated thrombotic microangiopathy masquerading as a pancreatic mass.Frontiers in medicine · 2026Article
- Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complement-mediated thrombotic microangiopathy (C-TMA), also referred to as atypical hemolytic uremic syndrome (aHUS), is a rare but severe cause of microangiopathic hemolysis and organ injury. Despite advances in understanding its pathophysiology and new nomenclature distinguishing C-TMA (aHUS) from other TMAs, diagnosis remains difficult because there is no single definitive diagnostic test. This update focuses on emerging data for functional complement assays (eg, modified Ham assay and human microvascular endothelial cell (HMEC-1) C5b-9 deposition assays) as adjunctive tests that may directly demonstrate complement hyperactivity in suspected C-TMA. A systematic diagnostic algorithm incorporating rapid exclusion of thrombotic thrombocytopenic purpura and Shiga toxin-producing Escherichia coli-HUS, careful evaluation of secondary causes, and integration of genetic and functional testing may improve diagnostic accuracy and guide the prompt use of targeted complement inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.